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Abstract: 32 
We describe a longitudinal study carried out in an adult outbreak-associated cohort to investigate 33 
health effects, including post-infectious irritable bowel syndrome, occurring after resolution of acute 34 
Cryptosporidium parvum infection. New symptoms self-reported up to 12 months included: weight 35 
loss (31%), abdominal pain (38%), diarrhoea (33%), eye pain (9%), joint pain (33%), fatigue (22%) and 36 
symptoms consistent with irritable bowel syndrome (IBS) (28%). Two people were medically 37 
diagnosed with IBS. This study describes for the first time sequelae reported by patients up to twelve 38 











  50 
Cryptosporidium is a protozoan parasite which causes symptoms of gastroenteritis including 51 
diarrhoea, vomiting and abdominal pain. It is the commonest cause of protozoal diarrhoea in the UK 52 
with nearly 6000 laboratory notifications in 2012 (Public Health England, 2014), and it particularly 53 
affects children aged between 2 and 5 years. Its global significance has become better recognised 54 
since publication of the Global Enteric Multi-centre Study (Kotloff et al., 2013), which found it to be 55 
the second commonest pathogen causing moderate to severe diarrhoea in children aged under 1 56 
year in low/middle income countries.  In immune-competent individuals cryptosporidiosis is often 57 
perceived as an unpleasant but relatively mild self-limiting illness. However there is growing 58 
evidence to suggest that, like certain bacterial causes of gastroenteritis, it may have longer-term 59 
health effects which manifest after resolution of the acute infection. The main two species affecting 60 
humans are C. hominis (predominantly anthroponotic) and C. parvum (both zoonotic and 61 
anthroponotic), and as might be expected the epidemiology differs between them. In addition, 62 
previous work has suggested that differences may exist in their post-infectious sequelae (Hunter et 63 
al., 2004; Bushen et al 2007). However there have been very few studies on this subject. 64 
 65 
In the UK, a case-control study of patients who had cryptosporidiosis found that infection with the 66 
species C. hominis (but not C. parvum) was associated with joint pain, eye pains, headaches and 67 
fatigue in the two months following infection (Hunter et al., 2004). A seronegative reactive arthritis 68 
has been reported in adults (Hay et al., 1987; Ozgul et al., 1999) and children (Shepherd et al., 1989; 69 
Cron et al., 1995) including one report of Reiter’s syndrome (arthritis, conjunctivitis and urethritis) 70 
(Cron et al., 1995). It has also been suggested that Cryptosporidium infection may cause Crohn’s 71 
disease and ulcerative colitis to relapse (Manthey et al., 1997; Colussi et al., 2010; Vadlamudi et al., 72 
2013). A study in Sweden (Rehn et al., 2015) followed up 459 cases who suffered C. hominis in two 73 
waterborne outbreaks and controls, finding that outbreak cases were more likely to report 74 
diarrhoea, abdominal pain and joint pain several months after infection than controls were. In terms 75 
of sequelae in developing countries, cryptosporidiosis is now recognized as being associated with 76 
stunting of growth, and with persistent diarrhoea. In studies in Brazil (among others), early 77 
childhood diarrhoea with Cryptosporidium was associated with impaired physical fitness and 78 
cognitive function 4-7 years later (Guerrant et al., 1999), and with increased diarrhoea morbidity in 79 
subsequent years (Agnew et al., 1998). It is therefore now believed that the effects of 80 
cryptosporidiosis go beyond the initial acute diarrhoeal episode, possibly due to an effect on the 81 
gastrointestinal epithelium (for example, villous blunting with chronic inflammation, and an 82 
association with the poorly understood entity ‘environmental enteropathy’) (see Bartelt et al., 83 
2013).  84 
 85 
Several agents of infectious gastroenteritis lead to an increased risk of developing irritable bowel 86 
syndrome (IBS). IBS is a common condition occurring in about 9-12% of the population in the UK 87 
(Jones et al., 2000). A validated diagnostic criteria assessment tool exists for IBS 88 
(http://romecriteria.org/). Post-infectious IBS (PI-IBS) is well-documented, occurring in 25-38% of 89 
patients with enteritis (Jones et al., 2000), for instance after Campylobacter, Salmonella or Shigella 90 
infection. People who have had a laboratory confirmed diagnosis of bacterial gastroenteritis are 91 
nearly 12 times more likely to develop new-onset IBS in comparison with people who have not had a 92 
laboratory diagnosis of bacterial gastroenteritis (Rodriguez et al., 1999).  PI-IBS appears to have a 93 
rather better prognosis than non-PI-IBS (Jones et al., 2000). For culture-confirmed bacterial 94 
gastroenteritis, a RR of 11.9 of new-onset IBS has been reported (Hanevik et al., 2009). This risk is 95 
not confined to bacterial infection but has also been documented with Giardia lamblia (Hanevik et 96 
al., 2009), another protozoan parasite causing gastroenteritis. Infection of a rat model with C. 97 
parvum triggers long-term jejunal hypersensitivity and mast cell accumulation, pathological changes 98 
akin to those found in human patients with IBS (Marion et al., 2006; Khaldi et al., 2009).  99 
 100 
During spring 2012, an outbreak of cryptosporidiosis caused by C. parvum occurred in the UK (mainly 101 
northern England) associated with consumption of pre-cut bagged salad leaves (McKerr et al., 2012). 102 
Just over 300 cases were identified and due to the nature of the products involved, most cases were 103 
adults. This was a rare opportunity to add to Hunter’s evidence (Hunter et al., 2004) relating to the 104 
sequelae of infection with C. parvum in adults. We undertook a longitudinal study among this adult 105 
outbreak-associated cohort to investigate health effects, including PI-IBS, occurring after resolution 106 
of acute C. parvum infection. 107 
 108 
 109 
Cases with illness onset between 14 May and 3 June 2012, aged ≥16 years, resident in northern 110 
England and confirmed as having C. parvum infection by the Cryptosporidium Reference Unit  were 111 
invited to participate in the study. Consenting participants completed a self-administered web-based 112 
questionnaire at 6 and 12 months after laboratory diagnosis of cryptosporidiosis (known as 6MQ and 113 
12MQ). We sought information about participants’ acute illness, as well as their symptoms and 114 
medical diagnoses prior to onset of acute cryptosporidiosis and during the following year. A review 115 
of previously reported health effects (Hunter et al., 2004; Hay et al., 1987; Ozgul et al., 1999; 116 
Shepherd et al., 1989; Cron et al., 1995; Manthey et al., 1997; Rehn et al., 2015) informed our 117 
inclusion of questions on specific symptoms and diagnoses, as well as some with no known 118 
association, such as diabetes and chest pain, included for comparison. To investigate reported 119 
symptoms consistent with a diagnosis of IBS the Rome III diagnostic criteria assessment tool 120 
(http://romecriteria.org/) was used. Participants were asked about the following conditions 121 
diagnosed by a medical practitioner: IBS, ulcerative colitis, Crohn’s disease, depression, anxiety, 122 
arthritis, diabetes or immunosuppression, either preceding their infection with Cryptosporidium or 123 
developing in the 12 months afterwards. In addition, data were also collected on self-reported 124 
symptoms, either consistent with IBS as indicated by Rome III criteria, weight loss, loss of appetite, 125 
nausea, recurrent vomiting, abdominal pain, diarrhoea, blood in stool, blurred vision, eye pain, 126 
recurrent headache, dizzy spells, fatigue, joint pain, back pain, fever or chest pain. Persons reporting 127 
pre-existing diagnosis or symptoms were excluded when enumerating new diagnosis or symptoms at 128 
6MQ and 12MQ.  129 
 130 
The results are shown in Table 1. One hundred and ninety seven potential participants were invited, 131 
of whom 54 (27%; 14 males and 40 females) took part. Response rates at 6MQ were significantly 132 
better among women than men (32.8 % vs 18.7%; difference 14.1 %, 95% CI 1.3% to 25.5%).   There 133 
was no statistically significant difference in the mean age of those who did (41.8 years) and did not 134 
(41.5 years) participate (p=0.18). The 12MQ was completed by 39 of the original 54 participants 135 
(retention rate 72%). Not all participants responded to each question, resulting in reduced 136 
denominators for some responses (Table 1). The mean duration of symptoms of acute 137 
cryptosporidiosis was 23 days (range 7-84 days). Six of 54 people spent a total of 95 days in hospital 138 
(mean hospital stay 15.8 days SD±13.3; range 2-34 days). Self-reported severity was described by 139 
32/53 (60%) as severe, 20/53 (38%) as moderate and 1/53 as mild. Among the cohort’s 41 140 
employees, 434 lost working days were reported. Pre-existing medically diagnosed IBS was reported 141 
by 11 of 54 (20%) participants, but this did not appear to correlate with the severity of acute 142 
cryptosporidiosis.  Those with pre-existing IBS reported a mean duration of illness of 24.8 days 143 
(SD±21.5; range 14-84 days); 2 of 11 were hospitalized for 2 and 5 days respectively; and 55% self-144 
reported their acute episode as severe. Seven (66%) reported their IBS symptoms were unchanged 145 
at 6MQ; 1 reported IBS symptoms had improved; 1 reported IBS symptoms had worsened and 2 146 
reported ‘not applicable’. At 12MQ, 4 of 9 (44%) responders with pre-existing IBS reported a 147 
worsening in their IBS symptoms.  At 6MQ, 4 of 43 (9%) people without pre-existing IBS reported 148 
symptoms which fulfilled all Rome III criteria for diagnosing IBS, including one person who received a 149 
new IBS diagnosis from a doctor. Combining reports from 6MQ and 12MQ, a total of six (14%) 150 
responders had symptoms meeting all Rome III criteria, and a total of two people received a new 151 
medical diagnosis of IBS.   Additionally, new onset gastrointestinal and non-gastrointestinal 152 
symptoms were reported  at 6MQ and/or 12MQ by a high proportion of participants including 153 
weight loss (31%), abdominal pain (38%), diarrhoea (33%), eye pain (9%), joint pain (33%), fatigue 154 
(22%) and dizzy spells (10%) (Table 1). 155 
 156 
This outbreak provided an unusual and fortuitous opportunity to recruit a cohort of adults with C. 157 
parvum, since a large proportion of Cryptosporidium cases usually occur in young children. 158 
Recruitment delay may have biased towards over-representation of those most adversely affected 159 
by, or those who attributed post-acute symptoms to, acute cryptosporidiosis. Hunter et al. (2004) 160 
reported new or worsened symptoms following cryptosporidiosis in 40.9% of case patients, including 161 
statistically significantly more cases than controls with weight loss (29.5%), appetite loss (23%), 162 
abdominal pain (26.2%) and diarrhoea (29.5%) at two months after acute infection. A study of a 163 
waterborne cryptosporidiosis outbreak in Milwaukee (Manthey et al., 1997) found that 39% of cases 164 
experienced a relapse of diarrhoeal symptoms after initial resolution, but this study did not follow 165 
patients up for longer than a maximum of three months, and in most cases for less than that. 166 
Evidence pertaining to periods longer than this is very scant. One study of cryptosporidiosis in 167 
Sweden (without controls) found persistent gastrointestinal symptoms in up to 8 of 53 (15%) 168 
patients 25-36 months post-infection: of interest, in this group, no difference was noted between 169 
cases who had been infected with C. hominis and those with C. parvum (Insulander et al., 2013). 170 
Another larger study (Rehn et al., 2015), also in Sweden, followed cases up at various time periods 171 
between 2.5 and 11.5 months post-C. hominis infection, in two locations, and found that 49% and 172 
56% of cases respectively reported symptoms during this period, with fatigue, headache, abdominal 173 
pain and diarrhoea being commonest. In our study, following C. parvum infection, cases reported 174 
new-onset weight loss (30.8%), loss of appetite (25%) abdominal pain (37.8%) and diarrhoea 175 
(33.3%). The figures are strikingly similar to Hunter’s et al (2004) and furthermore our study suggests 176 
persistence of these gastrointestinal symptoms beyond the two months studied by Hunter, and up 177 
to a year after acute cryptosporidiosis. Of interest also is that certain non-gastrointestinal sequelae 178 
were previously found to be significantly associated only with C. hominis (Hunter et al., 2004). For 179 
example, new onset eye pain was reported by 5/54 (9%) of our participants in either 6MQ or 12MQ 180 
in comparison with the previously reported nearly 10.9% of C. hominis and none of C. parvum cases 181 
with new or worsening eye pain (Hunter et al., 2004); new or worsening joint pain was found in 22% 182 
of cases in Hunter’s et al. study and 33% in ours. However, interpretation of our findings requires 183 
caution. Case numbers are small; there was no available control population (unlike Hunter’s et al. 184 
study), with cases simply acting as their own controls before and after infection; symptoms reported 185 
are common among the general adult population and recall bias may also have contributed.  186 
 187 
Medical diagnoses may underestimate the incidence of post-acute health effects. For example,  188 
although 15 of 46 (33%) participants reported new onset of joint pains at 6MQ and/or 12MQ, only 189 
three (20%) consulted healthcare services resulting in one new diagnosis of arthritis. Hunter also 190 
found that only about a third of those reporting joint pains intended to report it to a medical 191 
practitioner, and concluded that therefore the symptoms may have been relatively mild (Hunter et 192 
al., 2004). Among our participants 20% disclosed a pre-existing diagnosis of IBS, considerably greater 193 
than the reported UK population level of 9-12% (Jones et al., 2000). This could suggest that those 194 
with pre-existing IBS may more readily present to health services, or be more likely to have 195 
participated in our research study; alternatively, we cannot discount that those with IBS may be pre-196 
disposed to more symptomatic cryptosporidiosis. 197 
 198 
Four individuals without pre-existing IBS reported new symptoms that met Rome III criteria at 6MQ 199 
and a further 2 at 12MQ (14% in total). This does not necessarily equate to a diagnosis of IBS 200 
because other underlying pathological causes of symptoms must be excluded (by history, 201 
examination or clinical investigations) before considering IBS, and two people reported alternative 202 
plausible causes for their symptoms. The Rome III criteria are validated for the diagnosis of IBS, not 203 
specifically for PI-IBS, and require certain symptoms to be present for 6 months or more. It could be 204 
argued that duration of symptoms for diagnosing PI-IBS should be amended to ‘since resolution of 205 
acute infection’. If this were applied in our study, 8/43 (19%) participants without pre-existing IBS 206 
reported symptoms that met these modified criteria at 6MQ – there having hardly been a chance for 207 
them to have experienced symptoms of sequelae for 6 whole months. At 12MQ, 28% reported 208 
symptoms consistent with Rome III criteria for IBS if those with symptom duration shorter than 6 209 
months were included -  twice as many as the number reporting the same symptoms for 6  months 210 
or more. Two patients were diagnosed as having IBS by a medical practitioner during the 12 month 211 
period following infection. In summary, we found that within twelve months following acute C. 212 
parvum infection, two adults without pre-existing irritable bowel syndrome received a new medical 213 
diagnosis of IBS and up to 28% (12/43) self-reported new onset of IBS-consistent symptoms. PI-IBS 214 
appears to have a better prognosis than IBS diagnosed in the absence of recent known 215 
gastrointestinal infection (Jones et al., 2000), and usually resolves without medical intervention. 216 
Patients may gain reassurance if made aware of this potential longer term health effect and likely 217 
clinical course at the time of receiving their cryptosporidiosis diagnosis.  218 
The results presented here lend support to the notion of post-infectious sequelae after 219 
cryptosporidiosis. In addition this is the first time non-GI symptoms have been reported following C. 220 
parvum, as opposed to C. hominis infection. Despite the small number of participants and 221 
uncertainties discussed, the outcomes from this follow-up study add to available information on the 222 
self-reported and medically diagnosed health effects occurring following resolution of acute 223 
cryptosporidiosis.  Our ongoing work will compare self-reported symptoms among patients with C. 224 
hominis, C. parvum and without Cryptosporidium infection. Quantifying post-acute health sequelae 225 
assists healthcare and environmental health professionals in providing more complete advice and 226 
support to patients with cryptosporidiosis in a timely manner. In turn, this may reduce subsequent 227 
use of healthcare services such as repeated GP consultations and laboratory testing. Since, in the EU, 228 
there is no licensed treatment for cryptosporidiosis, identifying and increasing awareness of post-229 
acute health effects may assist policy decision-makers to understand the potential longer-term 230 




1. Agnew DG, Lima AA, Newman RD, Wuhib T, Moore RD, Guerrant RL, Sears CL. 235 
Cryptosporidiosis in northeastern Brazilian children: association with increased diarrhea 236 
morbidity. J Infect Dis. 1998;177:754–60. 237 
2. Bartelt LA, Lima AAM, Kosek M, Peñataro Yori P, Lee G, Guerrant RL. ‘‘Barriers’’ to Child 238 
Development and Human Potential: The Case for Including the ‘‘Neglected Enteric 239 
Protozoa’’ (NEP) and Other Enteropathy- Associated Pathogens in the NTDs. PLoS Negl 240 
Trop Dis. 2013;7:e2125.doi:10.1371/journal.pntd.0002125 241 
3. Bushen OY, Kohli A, Pinkerton RC, Dupnik K, Newman RD, Sears CL, Fayer R, Lima 242 
AAM, Guerrant RL. Heavy cryptosporidial infections in children in northeast Brazil: 243 
comparison of Cryptosporidium hominis and Cryptosporidium parvum. Trans R Soc Trop 244 
Med Hyg. 2007;101:378-84. 245 
4. Colussi O, Rouen A, Seksik P, Cosnes J, Beaugerie L, Sokol H. Acute cryptosporidiosis as a 246 
cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. J 247 
Crohns Colitis. 2010;4:669-70 248 
5. Cron RQ & Sherry DD. Reiter’s syndrome associated with cryptosporidial gastroenteritis. 249 
J Rheumatol. 1995;22:1962-3. 250 
6. Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL. Association of 251 
early childhood diarrhea and cryptosporidiosis with impaired physical fitness and 252 
cognitive function four-seven years later in a poor urban community in northeast Brazil. 253 
Am J Trop Med Hyg. 1999;61:707-13. 254 
7. Hanevik K, Dizdar V, Langeland N, Hausken T. Development of functional gastrointestinal 255 
disorders after Giardia lamblia infection. BMC Gastroenterol. 2009;9:27doi: 256 
10.1186/1471-230X-9-27. 257 
8. Hay EM, Winfield J, McKendrick MW. Reactive arthritis associated with Cryptosporidium 258 
enteritis. Br Med J (Clin Res Ed) 1987;295(6592):248. 259 
9. Hunter PR, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers RM et al. Health sequelae 260 
of human cryptosporidiosis in immunocompetent patients. Clin Infect Dis. 2004;39:504-261 
10. 262 
10. Insulander M, Silverlås C, Lebbad M, Karlsson L, Mattsson JG, Svenungsson B. Molecular 263 
epidemiology and clinical manifestations of human cryptosporidiosis in Sweden. 264 
Epidemiol Infect. 2013;141:1009-20. doi: 10.1017/S0950268812001665. 265 
11. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of 266 
Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 267 
(Suppl II) 2000;47:ii1-ii19.  268 
12. Khaldi S, Gargala G, Le Goff L, Parey S, Francois A, Fioramonti J et al. Cryptosporidium 269 
parvum  isolate-dependent postinfectious jejunal hypersensitivity and mast cell 270 
accumulation in an immunocompetent rat model. Infect Immun 2009;77:5163-9. 271 
13. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S et al. Burden 272 
and aetiology of diarrhoeal disease in infants and young children in developing countries 273 
(the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 274 
2013;382: 209–22. 275 
14. MacKenzie WR, Schell WL, Blair KA, Addiss DG, Peterson DE, Hoxie NJ et al. Massive 276 
outbreak of waterborne Cryptosporidium infection in Milwaukee, Wisconsin: recurrence 277 
of illness and risk of secondary transmission. Clin Infect Dis. 1995;21:57-62 278 
15. Manthey MW, Ross AB, Soergel KH. Cryptosporidiosis and inflammatory bowel disease. 279 
Experience from the Milwaukee outbreak. Dig Dis Sci. 1997;42:1580-6. 280 
16. Marion R, Baishanbo A, Gargala G, Francois A, Ducrotte P, Duclos C et al. Transient 281 
neonatal Cryptosporidium parvum infection triggers long-term jejunal hypersensitivity to 282 
distension in immunocompetent rats. Infect Immun. 2006;74:4387-9. 283 
17. McKerr C, Adak GK, Nichols G, Gorton R, Chalmers RM, Kafatos G et al.  An outbreak of 284 
Cryptosporidium parvum across England & Scotland associated with consumption of 285 
fresh pre-cut salad leaves, May 2012. PLoS One. 2015;10:e0125955 286 
18. Ozgül A, Tanyüksel M, Yazicioglu K, Arpacioglu O. Sacroiliitis associated with 287 
Cryptosporidium parvum in an HLA-B27–negative patient. Rheumatology 1999;38:288–9. 288 
19. Public Health England. Cryptosporidiosis, guidance, data and analysis. 2014. 289 
20. Rehn M, Wallensten A, Widerstrom M, Lilja M, Grunewald M, Stenmark S et al. Post-290 
infection symptoms following two large waterborne outbreaks of Cryptosporidium 291 
hominis in Northern Sweden, 2010-2011. BMC Public Health. 2015;15:529. doi: 292 
10.1186/s12889-015-1871-6. 293 
21. Rodriguez LA & Ruigomez A. Increased risk of irritable bowel syndrome after bacterial 294 
gastroenteritis. Br Med J. 1999;318:565-6. 295 
22. Shepherd RC, Smail PJ, Sinha GP. Reactive arthritis complicating cryptosporidial 296 
infection. Arch Dis Child. 1989;64:743–4. 297 
23. Vadlamudi N, Maclin J, Dimmitt RA, Thame KA. Cryptosporidial infection in children with 298 
inflammatory bowel disease. J Crohns Colitis. 2013;7:e337-43 299 
 300 
 301 
